Skip to main content

Start your patients on the #1 prescribed prostacyclin treatment.1*

Learn more

FOR US HEALTHCARE PROFESSIONALS ONLY

For the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability.

FOR US HEALTHCARE PROFESSIONALS ONLY

Request a Rep Referral Form
REFERRAL FORM

WHAT IS PAH?

PAH is a chronic disease that can progress rapidly2

PAH progressively limits blood flow in the lungs, which over time can severely impact the heart and may eventually lead to right heart failure.3,4

~1000 new cases each year in the US

It affects 15 to ~60 people per 1 million inhabitants in countries where studies have been conducted (~1000 new cases diagnosed each year in the United States)5-7

70-80% of cases are women

It’s more commonly diagnosed in women (70%-80% of cases) and in older patients (mid to late 40s)2,5,8*

Patients with PAH may unknowingly be at risk for disease progression9,10

The progression of PAH
Pulmonary arterial hypertension (PAH) disease progression

SOURCE: Adapted from Klinger JR. J Respir Dis. 2009.

*PAH is more frequently diagnosed in elderly patients in current registries, while the mean age of patients in the first US NIH registry was 36 years.5

Patients are at risk for disease progression, even if they are asymptomatic9,10

PAH affects 4 pathogenic pathways in patients8,11,12

endothelin more active
nitric oxide less active
prostacyclin less active
activin signaling more active

There are multiple therapeutic pathways for the treatment of PAH, and guidelines recommend targeting multiple pathways as the current standard of care. Prostacyclin is one of those pathways.11,13,14

Patients receiving treatment for more than one pathway have improved outcomes.11,15

LEARN MORE ABOUT THE PATHWAYS

See how prostacyclin therapy could make a difference for patients with PAH.

REVIEW MOA
man smiling as he prepares food in the kitchen